CA2365255A1 - Recepteur tr9 humain de facteurs de necrose des tumeurs - Google Patents

Recepteur tr9 humain de facteurs de necrose des tumeurs Download PDF

Info

Publication number
CA2365255A1
CA2365255A1 CA002365255A CA2365255A CA2365255A1 CA 2365255 A1 CA2365255 A1 CA 2365255A1 CA 002365255 A CA002365255 A CA 002365255A CA 2365255 A CA2365255 A CA 2365255A CA 2365255 A1 CA2365255 A1 CA 2365255A1
Authority
CA
Canada
Prior art keywords
amino acid
polypeptide
seq
receptor
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002365255A
Other languages
English (en)
Inventor
Jian Ni
Reiner L. Gentz
Guo-Liang Yu
Ping Fan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2365255A1 publication Critical patent/CA2365255A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)

Abstract

Cette invention concerne un nouveau membre de la famille des récepteurs des facteurs de nécrose des tumeurs, en particulier des molécules isolées d'acides nucléiques codant pour le récepteur TR9 humain. L'invention concerne également des poylypeptides en tant que vecteurs et cellules hôtes ainsi que des méthodes recombinantes permettant d'obtenir lesdits vecteurs et cellules hôtes. De plus, elle concerne des méthodes de recherche systématique d'agonistes et d'antagonistes de l'activité du récepteur TR9.
CA002365255A 1999-03-24 2000-03-16 Recepteur tr9 humain de facteurs de necrose des tumeurs Abandoned CA2365255A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12601999P 1999-03-24 1999-03-24
US60/126,019 1999-03-24
US13422099P 1999-05-14 1999-05-14
US60/134,220 1999-05-14
PCT/US2000/006831 WO2000056862A1 (fr) 1999-03-24 2000-03-16 Recepteur tr9 humain de facteurs de necrose des tumeurs

Publications (1)

Publication Number Publication Date
CA2365255A1 true CA2365255A1 (fr) 2000-09-28

Family

ID=26824194

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002365255A Abandoned CA2365255A1 (fr) 1999-03-24 2000-03-16 Recepteur tr9 humain de facteurs de necrose des tumeurs

Country Status (5)

Country Link
EP (1) EP1171579A4 (fr)
JP (1) JP2002542771A (fr)
AU (1) AU3628800A (fr)
CA (1) CA2365255A1 (fr)
WO (1) WO2000056862A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056892A1 (fr) * 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Recepteur humain tr9 du facteur de necrose tumorale
AU2001257008A1 (en) * 2000-05-10 2001-11-20 Eli Lilly And Company Treating t-cell mediated diseases by modulating dr6 activity
WO2003013585A1 (fr) * 2001-08-08 2003-02-20 Genset S.A. Agonistes et antagonistes de la mifaxine convenant au traitement de troubles du metabolisme au moyen
KR20050035511A (ko) * 2001-10-13 2005-04-18 아스테리온 리미티드 폴리펩타이드들을 포함하는 글리코실포스파티딜이노시톨
AU2002359459A1 (en) * 2001-12-17 2003-06-30 Eli Lilly And Company Treating b-cell mediated diseases by modulating dr6 activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114417A0 (en) * 1994-07-07 1995-10-31 Res Dev Foundation Tumor necrosis factor receptor-I associated proteins and protein kinase and methods for their use
US5563039A (en) * 1995-03-31 1996-10-08 Tularik, Inc. TNF receptor-associated intracellular signaling proteins and methods of use
WO1998056892A1 (fr) * 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Recepteur humain tr9 du facteur de necrose tumorale

Also Published As

Publication number Publication date
EP1171579A1 (fr) 2002-01-16
JP2002542771A (ja) 2002-12-17
WO2000056862A1 (fr) 2000-09-28
EP1171579A4 (fr) 2002-07-31
AU3628800A (en) 2000-10-09

Similar Documents

Publication Publication Date Title
US6358508B1 (en) Antibodies to human tumor necrosis factor receptor TR9
US6689607B2 (en) Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6433147B1 (en) Death domain containing receptor-4
US6743625B2 (en) Death domain containing receptor 5
US6503184B1 (en) Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6455040B1 (en) Tumor necrosis factor receptor 5
US7708996B2 (en) DR3 antibodies
US7186800B1 (en) Tumor necrosis factor 6α and 6β
US20020187526A1 (en) Neutrokine-alpha binding proteins and methods based thereon
US6506569B1 (en) Antibodies to human tumor necrosis factor receptor TR10
US20030092101A1 (en) Human tumor necrosis factor receptors TR13 and TR14
CA2369371A1 (fr) Recepteur 5 contenant le domaine de l'apoptose
CA2371114A1 (fr) Recepteurs contenant un domaine de mort cellulaire
US20020150583A1 (en) Tumor necrosis factor receptors 6alpha & 6beta
US20040013664A1 (en) Tumor necrosis factor receptors 6 alpha & 6 beta
CA2373063A1 (fr) Recepteur 4 contenant le domaine de la mort cellulaire programmee
AU774845B2 (en) Tumor necrosis factor receptors 6alpha and 6beta
US6713061B1 (en) Death domain containing receptors
US20030138426A1 (en) Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
CA2365255A1 (fr) Recepteur tr9 humain de facteurs de necrose des tumeurs
WO2000050459A1 (fr) Proteines tr11, tr11sv1, et tr11sv2 du type recepteur tnf humain
CA2374674A1 (fr) Recepteur 5 du facteur de necrose tumorale
AU782434B2 (en) Human tumor necrosis factor receptor TR16
CA2372246A1 (fr) Tr10, recepteur de facteur de necrose tumorale humain
US20020098163A1 (en) Human tumor necrosis factor receptors TR21 and TR22

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead